Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

74.950
+1.9002.60%
Volume:1.26M
Turnover:94.35M
Market Cap:22.41B
PE:-39.24
High:75.850
Open:73.050
Low:72.150
Close:73.050
52wk High:89.750
52wk Low:44.660
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:0.75
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.910
ROE:21.49%
ROA:-8.24%
PB:4.79
PE(LYR):-39.24
PS:22.98

Loading ...

KeyMed Biosciences FY Net Income Attributable RMB -522.6 Million

THOMSON REUTERS
·
Mar 26

Keymed Biosciences FY2025; Kangyueda sales climb to CNY 315 million; revenue rises to CNY 716 million

Reuters
·
Mar 26

Keymed Biosciences FY2025 revenue rises 67% to RMB716 million; operating loss widens to RMB521 million

Reuters
·
Mar 26

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

BRIEF-Keymed Biosciences Disposes Equity Interest In- Ouro Medicines

Reuters
·
Mar 24

KEYMED BIO-B to Gain Up to $320 Million from Gilead's Acquisition of Stake-Held Ouro Medicines

Stock News
·
Mar 24

Keymed Biosciences Sells 15% Stake in Ouro Medicines via US$2.18 Billion Gilead Merger, Eyes Up to US$320 Million Proceeds

Bulletin Express
·
Mar 24

KeyMed Biosciences Inc - Total Consideration up to $2.175 Bln

THOMSON REUTERS
·
Mar 24

KeyMed Biosciences - Expected Gain Group to Generate From Merger Comprising Upfront Payment of US$250 Mln, Others

THOMSON REUTERS
·
Mar 24

KeyMed Biosciences Inc - Disposal of Equity Interest in- Ouro Medicines

THOMSON REUTERS
·
Mar 24

Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca

Simply Wall St.
·
Mar 17

Keymed Biosciences (02162) Schedules 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express
·
Mar 16

Keymed Biosciences to Hold Board Meeting to Approve Annual Results and Consider Final Dividend

Reuters
·
Mar 16